Krystal Biotech Stock Return On Asset
| KRYS Stock | USD 179.19 2.37 1.34% |
Krystal Biotech fundamentals help investors to digest information that contributes to Krystal Biotech's financial success or failures. It also enables traders to predict the movement of Krystal Stock. The fundamental analysis module provides a way to measure Krystal Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Krystal Biotech stock.
Return On Assets is likely to gain to 0.01 in 2024. Krystal | Return On Asset |
Krystal Biotech Company Return On Asset Analysis
Krystal Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Krystal Biotech Return On Asset | 0.0031 |
Most of Krystal Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Krystal Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Krystal Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Krystal Biotech is extremely important. It helps to project a fair market value of Krystal Stock properly, considering its historical fundamentals such as Return On Asset. Since Krystal Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Krystal Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Krystal Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Krystal Total Assets
Total Assets |
|
Based on the latest financial disclosure, Krystal Biotech has a Return On Asset of 0.0031. This is 100.04% lower than that of the Biotechnology sector and 100.01% lower than that of the Health Care industry. The return on asset for all United States stocks is 102.21% lower than that of the firm.
Krystal Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Krystal Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Krystal Biotech could also be used in its relative valuation, which is a method of valuing Krystal Biotech by comparing valuation metrics of similar companies.Krystal Biotech is currently under evaluation in return on asset category among its peers.
Krystal Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Krystal Biotech from analyzing Krystal Biotech's financial statements. These drivers represent accounts that assess Krystal Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Krystal Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 232.8M | 880.6M | 1.6B | 2.0B | 3.4B | 3.5B | |
| Enterprise Value | 129.1M | 696.3M | 1.2B | 1.9B | 3.0B | 3.2B |
Krystal Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Krystal Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Krystal Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Krystal Fundamentals
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0031 | ||||
| Profit Margin | 0.64 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 4.6 B | ||||
| Shares Outstanding | 28.73 M | ||||
| Shares Owned By Insiders | 12.31 % | ||||
| Shares Owned By Institutions | 87.69 % | ||||
| Number Of Shares Shorted | 3.52 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 6.14 X | ||||
| Price To Sales | 30.97 X | ||||
| Revenue | 50.7 M | ||||
| EBITDA | (92.22 M) | ||||
| Net Income | 10.93 M | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 8.09 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.45 X | ||||
| Book Value Per Share | 29.22 X | ||||
| Cash Flow From Operations | (88.8 M) | ||||
| Short Ratio | 13.69 X | ||||
| Earnings Per Share | 3.94 X | ||||
| Target Price | 207.22 | ||||
| Number Of Employees | 229 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 5.15 B | ||||
| Total Asset | 818.36 M | ||||
| Retained Earnings | (269.83 M) | ||||
| Working Capital | 554.82 M | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
| Net Asset | 818.36 M |
About Krystal Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.